Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types
SAN DIEGO and CALGARY, AB , Feb. 18, 2025 /CNW/ -- Oncolytics Biotech ® Inc. ( NASDAQ : ONCY ) ( TSX : ONC ), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy , pelareorep : the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology ( ASCO ) Gastrointestinal Cancers Symposium in late January.
"We're hitting critical milestones that validate our progress and set the stage for what we believe will be an exciting year," said Wayne Pisano , Interim CEO and Chair of Oncolytics' Board of Directors. "With positive feedback from regulators in place, we're advancing our pancreatic cancer study toward full enrollment, and our ASCO GI presentations highlighted pelareorep's strong safety and efficacy results in two hard-to-treat cancers. We remain focused on bringing new treatment options to patients while creating value for shareholders as we move forward in 2025."
German Regulatory Agency Gives Green Light for Pancreatic Cancer Study to Continue as Planned
Approval to Fully Enroll the Cohort Secured: Germany's Paul-Ehrlich-Institute (PEI) has given Oncolytics the go-ahead to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) after a positive safety review.
What This Means: Pelareorep, in combination with modified FOLFIRINOX with and without atezolizumab, is now progressing toward full enrollment, with 30 patients set to participate in Stage 1 across the two treatment arms.
Next Steps: Oncolytics will continue to collect safety data, and an initial efficacy readout is expected later this year.
ASCO GI 2025 Data Confirms Pelareorep's Potential in Pancreatic and Anal Cancers
At ASCO GI 2025, Oncolytics presented new clinical results demonstrating pelareorep's potential in two challenging cancer types:
Anal Cancer: Patients receiving pelareorep + atezolizumab continue to show stronger responses than expected based on published studies with checkpoint inhibitors alone.
Pancreatic Cancer: Pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel, and atezolizumab. The most recent data supports a favorable safety profile when combining pelareorep with a different chemotherapy regimen (modified FOLFIRINOX) with and without the checkpoint inhibitor atezolizumab, potentially expanding its treatment applications.
Why This Matters: These findings further de-risk pelareorep's development and could pave the way for larger registration-enabling clinical trials in these indications.
Looking Ahead: More Catalysts in 2025
Oncolytics is entering a pivotal year with multiple upcoming milestones, including:
Additional data readouts from ongoing trials in gastrointestinal cancers, including translational results that further characterize pelareorep's mechanism of action.
Interactions with Regulatory Agencies that could accelerate future trials and move pelareorep closer to potential registration-enabling studies in breast cancer and gastrointestinal cancers.
"We're seeing clinical validation across multiple studies," added Pisano. "With encouraging regulatory interactions in hand and data readouts ahead, 2025 is shaping up to be an exciting year for Oncolytics and our investors. As we have shown in GOBLET, BRACELET-1, and numerous previous studies, pelareorep has a favorable safety profile and efficacy signals across multiple indications with a high unmet need. We are excited about the potential for moving to a registration-enabling study in breast cancer and advancing our clinical program in gastrointestinal cancers."
About GOBLET
The GOBLET (G astrointestinal tum O rs exploring the treatment com B inations with the oncolytic reovirus pe L ar E orep and an T i-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in Germany and is being managed by AIO-Studien-gGmbH . The co-primary endpoints of the study are objective response rate ( ORR ) and/or disease control rate and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers. Favorable safety and positive clinical efficacy signals have been seen in the pancreatic and anal cancer cohorts.
About GOBLET Cohort 5
The modified FOLFIRINOX (mFOLFIRINOX) cohort of the Phase 1/2 GOBLET study is designed to evaluate newly diagnosed metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep + mFOLFIRINOX with or without atezolizumab. A three-patient safety run-in was incorporated to evaluate the safety and tolerability of each treatment arm: pelareorep + mFOLFIRINOX + atezolizumab and pelareorep + mFOLFIRINOX. A total of fifteen evaluable patients will be randomized to each arm in Stage 1 of this Simon two-stage study. The co-primary endpoints are objective response rate and safety. If Stage 1 success criteria are met, one or both treatment arms may be expanded to Stage 2, in which 17 additional evaluable patients per arm will be enrolled. Blood and tumor samples will also be collected for translational evaluations.
About AIO
AIO-Studien-gGmbH (AIO) emerged from the study center of the medical oncology working group within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on medical oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it prepares for registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @ oncolytics.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans to advance our pancreatic cancer study toward full enrollment; our focus on bringing new treatment options to patients while creating value for shareholders as we move forward in 2025; our plans to continue to collect safety data; the anticipated timing of an initial efficacy readout; our belief that our new clinical results in anal and pancreatic cancer further de-risk pelareorep's development and could pave the way for larger registration-enabling clinical trials in these indications; our upcoming milestones, including additional data readouts and interactions with regulatory agencies; our belief that pelareorep is poised to advance to registration-enabling studies for the treatment of breast and pancreatic cancers; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
Media Contact for Oncolytics
Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 hours ago
- Cision Canada
Xinhua Silk Road: Yinchuan supports China's wine industry in going global
BEIJING, June 14, 2025 /CNW/ -- The Fifth China (Ningxia) International Wine Culture and Tourism Expo, alongside the 32nd Concours Mondial de Bruxelles, was held in Yinchuan, capital of northwest China's Ningxia Hui Autonomous Region, from June 9 to 12, contributing to the global dialogue of wine industries worldwide. In recent years, Yinchuan has been committed to building a "world capital of wine." A series of supportive policies have been rolled out to boost investment, introduce advanced technologies, and promote international cooperation. Yinchuan now boasts the most concentrated wine grape production cluster in China, with a total of 273,000 mu (about 18,200 hectares) of vineyards, gathering155 wineries and grape-growing enterprises. In addition, Yinchuan's annual wine output reached 75 million bottles in 2024, accounting for approximately 26.8 percent of the total output of domestically produced estate wines. 19 types of local wine have been selected as national gifts and exported to more than 40 countries and regions. The eastern foothills of the Helan Mountains in Ningxia used to be barren and sandy years ago. In order to restore the ecosystem, Yinchuan has pursued an integrated approach in the protection and improvement of mountains, rivers, forests, farmland, lakes, grasslands, and deserts. Meanwhile, guided by the coordinated development of "ecology + industry" , the city has advanced ecological restoration in the eastern foothills of Helan Mountains while promoting the integrated growth of the wine industry, cultural tourism, and ecological conservation. These efforts have fostered high-quality development that balances resource utilization with ecological governance, and aligns economic growth with environmental protection. Furthermore, at the wineries along the eastern foothills of Helan Mountains, every step is carefully monitored by winery staff to ensure premium quality of grapes, from science-based planting to cutting-edge winemaking technologies. As the birthplace and hub of Ningxia's wine industry, Yinchuan is stepping up efforts to build itself into a "world capital of wine" with high standards. The city is now home to 37 classified wineries and 53 enterprises with certified geographical indications, and its wine industry recorded a total output value of 36 billion yuan (about 5.02 billion U.S. dollars) in 2024.
Cision Canada
4 hours ago
- Cision Canada
IDC Report: Huawei Ranks No.1 in Global Wrist-Worn Market in Q1
H u awei wearable devices Surpassed 200 Million Cumulative Shipments SHENZHEN, China, June 14, 2025 /CNW/ -- According to the latest IDC Worldwide Quarterly Wearable Device Tracker data, Huawei ascended to the top position in the global wrist-worn device market in Q1 2025, while maintaining robust growth momentum and retaining its leadership in shipment volume within China. Additionally, as of 5 June 2025, Huawei's cumulative global wearable shipments have exceeded 200 million units. Five Product Series Catering to Global Users' Diverse Scenario Needs Huawei wearables integrate fashionable design, professional and comprehensive sports and health features, and efficient, practical smart experiences. Tailored to different user needs, Huawei has developed five product series to fulfil the diverse scenario requirements of all user groups—spanning smart living, scientific exercise, and health management. The HUAWEI WATCH Series incorporates cutting-edge smart technology, featuring standalone calling capabilities and smart vehicle control functions to enable an efficient, intelligent lifestyle. The newly launched HUAWEI WATCH 5 delivers enhanced intelligence, efficiency and convenience. Equipped with the innovative multi-sensing X-TAP technology, it unlocks new dimensions in health monitoring and tactile interaction. The HUAWEI WATCH FIT Series fulfils lightweight wear needs through its slim design and extensive sports functions, allowing users to fully enjoy daily life. Meanwhile, the HUAWEI WATCH GT Series combines exceptional battery life with fashionable aesthetics and professional sports health features, serving as a comprehensive wrist-worn fitness coach. For users who push boundaries and challenge extremes, the HUAWEI WATCH Ultimate Series delivers ultimate reliability with its rugged construction, advanced sports modes including 100-metre professional diving and outdoor expedition features, as well as advanced golf course mode, to bring cater to users' needs. Additionally, addressing hypertension management challenges, Huawei innovatively broke through wrist-based blood pressure technology to launch the HUAWEI WATCH D Series. Through its breakthrough 24-hour dynamic blood pressure monitoring function, it helps users measure and manage blood pressure anytime, anywhere, integrating professional-grade blood pressure health guardianship into daily life. Technological Innovation Driving Breakthroughs in Sports Health Technology Behind the satisfaction of users' sports health management needs lies Huawei wearables' continuous innovation investment. Huawei has established three Health Labs globally, leveraging capabilities from over ten Huawei research institutes to relentlessly explore the frontiers of sports health technology. In 2024, Huawei launched its new digital health & fitness paradigm—TruSense System—achieving higher accuracy and speed in vital sign data monitoring. In 2025, the TruSense System was upgraded again, fusing the advantages of fingertip and wrist detection to deliver a fuller, more accurate, and faster health monitoring experience, including 10-second fingertip blood oxygen readings and an increase in micro-body measurement indicators to 17 items. In the field of blood pressure management, Huawei pioneered the launch of the HUAWEI WATCH D, a wrist-based blood pressure monitor that obtained Class II medical device registration certification in China. Now this innovation included in the "Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)". As of now, Huawei wearable devices have obtained 7 domestic medical certifications and medical device certificates in 13 overseas countries/regions, with nearly 1000 patent applications in the smart wearables field. Huawei has collaborated with over 160 global professional institutions, conducted 300+ health research projects, and attracted over 17 million users to participate in health studies. Huawei accompanies global users to build sports health lifestyles together. In September 2023, Huawei initiated the "Light Up Your Rings" campaign, which has seen over 6 million global users participate, lighting up rings over 300 million times. In 2025, the fully upgraded "Active Rings" initiative was introduced, inspiring global users to move joyfully anytime, anywhere with Huawei wearables. The Active Rings campaign has already been held in Germany, Spain, and China, and beyond, where consumers jointly enjoyed active moments. It will progressively launch in APAC, Latin America, the Middle East, and other regions in the future.
Globe and Mail
6 hours ago
- Globe and Mail
3 Must-Know Facts About Five Below You'll Want to Check Out Before Buying the Stock
Shares of Five Below (NASDAQ: FIVE) are trading 48% below their peak (as of June 10), which was established in August 2021. Clearly, the company has a long way to go to get back to its former glory. However, shares are surging recently, up 102% just in the past two months. The market is building up the momentum for Five Below, taking a more bullish stance. And this might be a compelling reason to consider adding the shares to your portfolio. If you're looking to buy this retail stock, take the time to learn these three things first. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Expanding at a brisk pace The rise of online shopping in the past couple of decades has been widely publicized. This is clear when looking at successful tech-driven enterprises like Amazon and Shopify that have helped support adoption of online shopping. However, consumers still like to shop in person; 84% of retail spending in the U.S. still takes place in a brick-and-mortar setting. And this has benefited a company like Five Below, which has rapidly expanded over the years. As of May 3, it had 1,826 stores scattered across the U.S. That figure is up nearly fivefold from 385 exactly a decade ago. Management has huge ambitions. "We still believe that there's an opportunity here for 3,500 stores," Chief Operating Officer Kenneth Bull said on the fiscal Q4 2024 earnings call in March. You'd probably struggle to find other retailers that are trying to grow their physical presence like this. But it makes sense why. Five Below's unit economics appear to be in good shape. A new location costs about $500,000 to open, but it can generate on average $2.2 million in revenue and $500,000 in earnings before interest, taxes, depreciation, and amortization (EBITDA) in the first year. There remains sizable opportunity to expand in very populated states like California, Texas, Florida, New York, and Pennsylvania. Should Five Below reach this target, its revenue base should be much higher than it is today. Success in a tough industry There might be no industry more competitive than the retail sector. Consumers have unlimited choices on where to spend their money. There is no lock-in that retailers can benefit from. Margins are typically already thin. Consumers have ever-changing preferences and expectations. And there are low barriers to entry. That's why it's impressive to see the momentum Five Below has right now. During the first quarter of fiscal 2025 (ended May 3), the company reported 19.5% year-over-year revenue growth. This gain was driven by a 7.1% jump in same-store sales (SSS), which benefited from strong foot traffic. Management expects SSS to increase by 3% to 5% for the full fiscal year. While this indicates there will be a slowdown in the near term, it's encouraging to see this key performance metric growing. That's especially true in the current economic environment that could force consumers to be more critical about their spending habits. Valuation matters to investors Five Below might be trading well off its peak. However, the fact that the stock has rocketed higher since early April creates a more difficult setup for prospective investors. The best opportunities come when shares are priced attractively. I don't believe this is the case here. Investors can buy the stock at a price-to-earnings ratio of 25.9. This represents a notable discount to the trailing three-year average. But it's a slight premium to the overall S&P 500 index. This provides no margin of safety, in my view. That's because Wall Street consensus analyst estimates call for earnings per share to rise at just a 6% compound annual rate between fiscal 2024 and fiscal 2027. That weak forecast won't necessarily bode well for the stock price. If the valuation comes down, interested investors have a better understanding of Five Below's growth outlook, as well as its recent fundamental momentum, to make an informed decision. Should you invest $1,000 in Five Below right now? Before you buy stock in Five Below, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Five Below wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
